You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

How Important Is Sleep Architecture for Sleep Quality?

  • Authors: Geert Mayer, MD​; Göran Hajak, MD, PhD, MBA; Thomas Scammell, MD ​
  • CME / ABIM MOC / CE Released: 7/20/2022
  • Valid for credit through: 7/20/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for a US and European audience of primary care physicians, psychiatrists, neurologists, and nurses. 

The goal of this activity is that learners will be better able to improve understanding of the consequences of disrupted sleep architecture in insomnia and the impact of current and emerging therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Consequences of disrupted sleep architecture on physiology
    • Impact of gamma-aminobutyric acid (GABA)ergic therapies on sleep architecture 
    • Impact of dual orexin receptor antagonists (DORAs) on sleep architecture 


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Geert Mayer, MD

    Associate Professor​
    Department of Neurology ​
    Philipps-Universität Marburg​
    Marburg, Germany

    Disclosures

    Disclosure: Geert Mayer, MD, has the following relevant financial relationships:
    Consultant or advisor for: Janssen Pharma Germany; Jazz Pharma Oxford UK; NLS Pharma Switzerland
    Speaker or member of speakers bureau for: Idorsia UK; Jazz Pharma UK

  • Göran Hajak, MD, PhD, MBA

    Professor of Psychiatry​
    University of Regensburg​
    Director​
    Department of Psychiatry
    Psychosomatic Medicine and Psychotherapy ​
    Social Foundation ​
    Bamberg, Germany

    Disclosures

    Disclosure: Göran Hajak, MD, PhD, MBA, has the following relevant financial relationships:
    Consultant or advisor for: Heel; Idorsia; Janssen-Cilag; Jazz Pharmaceuticals; Recordati S.p.A.; Rovi; Sanofi; SERVIER
    Speaker or member of speakers bureau for: Bristol-Myers Squibb Company; Gedeon Richter; H. Lundbeck A/S; Heel; Hexal; Idorsia; Janssen-Cilag; Jazz Pharmaceuticals, Inc.; Medau; Medfora; Medici; Neuraxpharm; Pfizer Inc.; Recordati S.p.A.; Repha; Rovi; Sanofi; Schwabe Pharmaceuticals; SERVIER; Zeller
    Contracted researcher for: CGC-Consulting

  • Thomas Scammell, MD

    Professor of Neurology​
    Harvard Medical School​
    Boston, MA, United States 

    Disclosures

    Disclosure: Thomas Scammell, MD, has the following relevant financial relationships:
    Consultant or advisor for: Avadel; Idorsia; Harmony Biosciences; Jazz Pharmaceuticals; Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.
    Research funding from: Harmony Biosciences; Jazz Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.

Editors

  • Katherine Carpenter, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Katherine Carpenter, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Eisai Inc.; GW Pharmaceuticals 

  • Diana Lucifero, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Diana Lucifero, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

How Important Is Sleep Architecture for Sleep Quality?

Authors: Geert Mayer, MD​; Göran Hajak, MD, PhD, MBA; Thomas Scammell, MD ​Faculty and Disclosures

CME / ABIM MOC / CE Released: 7/20/2022

Valid for credit through: 7/20/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Normal Sleep Architecture and the Impact of Sleep Disorders

Dr Mayer introduces the concept of sleep structure and how it become disrupted in sleep disorders.
Geert Mayer, MD

Impact of Disrupted Sleep Patterns

Dr Mayer describes the factors that underlie sleep quality and the consequences of sleep disruption.
Geert Mayer, MD

Insomnia Medication and Sleep Architecture: GABA-Targeting Therapies

Dr Hajak provides an overview of insomnia treatments that target the GABAergic system.
Göran Hajak, MD, PhD, MBA

Insomnia Medications and Sleep Architecture: Orexin-Targeting Therapies

Dr Scammell concludes with an overview of orexin neuropeptides and their potential as insomnia treatment targets.
Thomas Scammell, MD
 

Educational Impact Challenge

The goal of this activity is that learners will be better able to improve understanding of the consequences of disrupted sleep architecture in insomnia and the impact of current and emerging therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print